Compare DPZ & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPZ | GH |
|---|---|---|
| Founded | 1960 | 2011 |
| Country | United States | United States |
| Employees | 10200 | N/A |
| Industry | Food Distributors | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 13.3B |
| IPO Year | 2004 | 2018 |
| Metric | DPZ | GH |
|---|---|---|
| Price | $374.75 | $88.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 19 |
| Target Price | ★ $472.74 | $120.05 |
| AVG Volume (30 Days) | 932.3K | ★ 1.7M |
| Earning Date | 04-27-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | 5.27 | ★ 6.74 |
| EPS | ★ 17.57 | N/A |
| Revenue | ★ $4,939,994,000.00 | $982,021,000.00 |
| Revenue This Year | $8.08 | $33.30 |
| Revenue Next Year | $4.03 | $28.19 |
| P/E Ratio | $21.26 | ★ N/A |
| Revenue Growth | 4.96 | ★ 32.88 |
| 52 Week Low | $346.31 | $36.36 |
| 52 Week High | $499.08 | $120.74 |
| Indicator | DPZ | GH |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 45.58 |
| Support Level | $370.70 | $82.33 |
| Resistance Level | $418.07 | $90.28 |
| Average True Range (ATR) | 10.17 | 4.76 |
| MACD | 2.15 | 0.97 |
| Stochastic Oscillator | 77.89 | 34.32 |
Domino's is the world's largest pizza chain, surpassing $20 billion in system sales with over 22,100 stores across more than 90 markets at the end of 2025. Around 33% of its units are in the US. The business is 99% franchised. Domino's operates through three segments: supply chain (60% of revenue), US stores (33%), and international franchises (7%). The firm generates the bulk of its revenue by supplying food to stores in the US and Canada through a vertically integrated network of 25 manufacturing and supply chain facilities, which primarily produce and distribute dough, and collecting brand royalties and marketing fees from franchisees. Domino's also generates revenue from sales at company-owned stores.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.